Collaboration leads to new antibody media
New antibody media for affinity chromatography has been created by two firms in the industry

Solid phase extraction (SPE)

Collaboration leads to new antibody media

17 Aug, 2010

Published over 16 years ago. See the latest and most current information on Solid phase extraction (SPE).

Collaboration between antibody-based affinity purification technology provider BAC BV and human proteins provider Octapharma has led to the development of a new affinity ligand for purifying human cell cultures.

G-CSF CaptureSelect is licensed to Octapharma for use in purifying recombinant human granulocyte-colony stimulating factor, or G-CSF.

Kim Bjornstrup, vice-chairman of Octapharma, explains that the two companies' previous work led to the development.

"The start of this collaboration with BAC, in G-CSF, came from the success with our previous collaboration to develop a ligand for the purification of factor IX," the spokesman says.

With the ligand, Octapharma aims to cut the downstream development time needed in order to produce the recombinant protein, as well as raising the overall recovery of the process compared with conventional techniques.

Octapharma was founded in 1983 and has grown to employ more than 4,000 people, with sales in 2009 surpassing the €1 billion (£820 million) benchmark.

Latest News

Explore Our Other Sites

Labmate Online
Smart temperature control. Designed for the future.
Explore more Arrow
Envirotech Online
Vehicle-based methane detection system passes German suitability test
Explore more Arrow
Pollution Solutions Online
Large-scale liquefied biogas bunkering to become possible in the Port of Gothenburg in 2027
Explore more Arrow
Petro Online
PFAS reference standard combines ten analytes to support trace-level calibration
Explore more Arrow